337 related articles for article (PubMed ID: 27249687)
1. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Kluetz PG; Chingos DT; Basch EM; Mitchell SA
Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
[TBL] [Abstract][Full Text] [Related]
2. Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug development.
Xia H; Booth BP; Wang Y; Fan C; Bhatnagar V; Kluetz P; Fourie Zirkelbach J
J Patient Rep Outcomes; 2023 Nov; 7(1):116. PubMed ID: 37975967
[TBL] [Abstract][Full Text] [Related]
3. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Basch E; Reeve BB; Mitchell SA; Clauser SB; Minasian LM; Dueck AC; Mendoza TR; Hay J; Atkinson TM; Abernethy AP; Bruner DW; Cleeland CS; Sloan JA; Chilukuri R; Baumgartner P; Denicoff A; St Germain D; O'Mara AM; Chen A; Kelaghan J; Bennett AV; Sit L; Rogak L; Barz A; Paul DB; Schrag D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265940
[TBL] [Abstract][Full Text] [Related]
4. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
[TBL] [Abstract][Full Text] [Related]
5. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Hay JL; Atkinson TM; Reeve BB; Mitchell SA; Mendoza TR; Willis G; Minasian LM; Clauser SB; Denicoff A; O'Mara A; Chen A; Bennett AV; Paul DB; Gagne J; Rogak L; Sit L; Viswanath V; Schrag D; Basch E;
Qual Life Res; 2014 Feb; 23(1):257-69. PubMed ID: 23868457
[TBL] [Abstract][Full Text] [Related]
6. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.
Atkinson TM; Ryan SJ; Bennett AV; Stover AM; Saracino RM; Rogak LJ; Jewell ST; Matsoukas K; Li Y; Basch E
Support Care Cancer; 2016 Aug; 24(8):3669-76. PubMed ID: 27260018
[TBL] [Abstract][Full Text] [Related]
7. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Basch E; Becker C; Rogak LJ; Schrag D; Reeve BB; Spears P; Smith ML; Gounder MM; Mahoney MR; Schwartz GK; Bennett AV; Mendoza TR; Cleeland CS; Sloan JA; Bruner DW; Schwab G; Atkinson TM; Thanarajasingam G; Bertagnolli MM; Dueck AC
Clin Trials; 2021 Feb; 18(1):104-114. PubMed ID: 33258687
[TBL] [Abstract][Full Text] [Related]
8. Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.
Davis S; Edwards T; Norcross L; Fehnel S; Beaudet A; Eckart M; Fastenau J
J Patient Rep Outcomes; 2023 Dec; 7(1):134. PubMed ID: 38108945
[TBL] [Abstract][Full Text] [Related]
9. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bennett AV; Dueck AC; Mitchell SA; Mendoza TR; Reeve BB; Atkinson TM; Castro KM; Denicoff A; Rogak LJ; Harness JK; Bearden JD; Bryant D; Siegel RD; Schrag D; Basch E;
Health Qual Life Outcomes; 2016 Feb; 14():24. PubMed ID: 26892667
[TBL] [Abstract][Full Text] [Related]
10. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
Basch E; Dueck AC; Rogak LJ; Minasian LM; Kelly WK; O'Mara AM; Denicoff AM; Seisler D; Atherton PJ; Paskett E; Carey L; Dickler M; Heist RS; Himelstein A; Rugo HS; Sikov WM; Socinski MA; Venook AP; Weckstein DJ; Lake DE; Biggs DD; Freedman RA; Kuzma C; Kirshner JJ; Schrag D
JAMA Oncol; 2017 Aug; 3(8):1043-1050. PubMed ID: 28208174
[TBL] [Abstract][Full Text] [Related]
11. A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events.
Janse van Rensburg HJ; Liu Z; Watson GA; Veitch ZW; Shepshelovich D; Spreafico A; Abdul Razak AR; Bedard PL; Siu LL; Minasian L; Hansen AR
Br J Cancer; 2023 Sep; 129(4):612-619. PubMed ID: 37419999
[TBL] [Abstract][Full Text] [Related]
12. Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Miyaji T; Iioka Y; Kuroda Y; Yamamoto D; Iwase S; Goto Y; Tsuboi M; Odagiri H; Tsubota Y; Kawaguchi T; Sakata N; Basch E; Yamaguchi T
J Patient Rep Outcomes; 2017; 1(1):8. PubMed ID: 29757296
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE.
Watson GA; Veitch ZW; Shepshelovich D; Liu ZA; Spreafico A; Abdul Razak AR; Bedard PL; Siu LL; Minasian L; Hansen AR
Br J Cancer; 2022 Nov; 127(9):1629-1635. PubMed ID: 36008705
[TBL] [Abstract][Full Text] [Related]
14. Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period.
Lee MK; Basch E; Mitchell SA; Minasian LM; Langlais BT; Thanarajasingam G; Ginos BF; Rogak LJ; Mendoza TR; Bennett AV; Schrag D; Mazza GL; Dueck AC
Qual Life Res; 2023 Jul; 32(7):2047-2058. PubMed ID: 36897529
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501).
Snyder RA; Dueck AC; Fruth B; Shi Q; Hubbard JM; Herman JM; O'Reilly EM; Katz MHG
Ann Surg; 2023 Oct; 278(4):598-608. PubMed ID: 37334719
[TBL] [Abstract][Full Text] [Related]
16. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events.
Gilbert A; Piccinin C; Velikova G; Groenvold M; Kuliś D; Blazeby JM; Bottomley A
J Clin Oncol; 2022 Nov; 40(32):3770-3780. PubMed ID: 35973158
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer.
Suzuki Y; Iwamoto T; Uno M; Hatono M; Kajiwara Y; Takahashi Y; Kochi M; Shien T; Kikawa Y; Uemura Y; Hagiwara Y; Yamamoto S; Taira N; Doihara H; Toyooka S
Breast Cancer; 2023 Sep; 30(5):856-868. PubMed ID: 37422608
[TBL] [Abstract][Full Text] [Related]
18. An adverse event capture and management system for cancer studies.
Lencioni A; Hutchins L; Annis S; Chen W; Ermisoglu E; Feng Z; Mack K; Simpson K; Lane C; Topaloglu U
BMC Bioinformatics; 2015; 16 Suppl 13(Suppl 13):S6. PubMed ID: 26424052
[TBL] [Abstract][Full Text] [Related]
19. Electronic-PRO Measures for adverse events Of Treatment In ONcology (E-PROMOTION).
Pradhan A; Dwivedi P; Pareek P; Kalra S; Singh S; Varthya SB; Goel AD; Shamim MA; Vishnoi JR; Sharma PP; Pradhan A; Ambwani S; Misra S
Int J Med Inform; 2024 Feb; 182():105305. PubMed ID: 38061185
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.
Basch E; Dueck AC; Rogak LJ; Mitchell SA; Minasian LM; Denicoff AM; Wind JK; Shaw MC; Heon N; Shi Q; Ginos B; Nelson GD; Meyers JP; Chang GJ; Mamon HJ; Weiser MR; Kolevska T; Reeve BB; Bruner DW; Schrag D
J Clin Oncol; 2018 Sep; 36(31):JCO2018788620. PubMed ID: 30204536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
